Purpura, Thrombotic Thrombocytopenic - 25 Studies Found
Withdrawn |
: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura : Purpura, Thrombotic Thrombocytopenic : 2012-12-12 :
|
Terminated |
: IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients : Purpura, Thrombotic Thrombocytopenic : 2016-07-27 : Biological: HMed-IdeS One dose of 0.25 mg/kg BW HMed-IdeS on study day 0. Following and evaluation of ef |
Recruiting |
: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) : Thrombotic Thrombocytopenic Purpura : 2009-08-04 : Drug: Danazol Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time o |
Completed |
: ADAMTS13 in Thrombotic Thrombocytopenic Purpura : Thrombotic Thrombocytopenic Purpura : 2007-01-24 |
Withdrawn |
: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura : Thrombotic Thrombocytopenic Purpura : 2005-11-07 : Drug: Rituximab Rituximab will be administered immediately after pheresis to minimize the amount of Ritu |
Completed |
: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura : Thrombotic Thrombocytopenic Purpura : 2009-05-22 : Drug: rituximab Patients will be treated according to the recommendations of the Reference Centre for th |
Active, not recruiting |
: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) : Thrombotic Thrombocytopenic Purpura : 2008-07-09 :
|
Completed |
: Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP) : Thrombotic Thrombocytopenic Purpura : 2010-06-25 :
|
Recruiting |
: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura : Acquired Thrombotic Thrombocytopenic Purpura : 2015-09-14 :
|
Recruiting |
: The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) : Thrombotic Thrombocytopenic Purpura (TTP) : 2009-07-09 : Drug: Rituximab Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infus |